[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis.
James B LillekerRichard HodgsonMark RobertsKarl HerholzJames HowardRainer HinzGabriela Arredondo Hector ChinoyPublished in: Annals of the rheumatic diseases (2019)
[18F]florbetapir amyloid positron emission tomography differentiates IBM from PM. Successful development could facilitate accurate diagnosis, inclusion in clinical trials and help avoid unnecessary exposure to potentially harmful treatments.
Keyphrases
- positron emission tomography
- computed tomography
- clinical trial
- interstitial lung disease
- pet ct
- particulate matter
- systemic sclerosis
- pet imaging
- air pollution
- skeletal muscle
- high resolution
- rheumatoid arthritis
- randomized controlled trial
- phase ii
- idiopathic pulmonary fibrosis
- mass spectrometry
- risk assessment
- water soluble